Loading...
Loading...
Actavis plc
ACT today announced
that it has launched a generic version of Intuniv(R) (guanfacine
hydrochloride), as part of a settlement agreement with Shire plc. Actavis
has begun shipping the product and, under applicable Hatch Waxman rules, is
entitled to 180 days of marketing exclusivity.
Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO
Intuniv(R) is a prescription medicine used to treat Attention Deficit
Hyperactivity Disorder in patients ages 6 to 17. For the 12-month period
ending June 30, 2014, Intuniv(R) had U.S. sales of approximately $668
million, according to IMS Health data.
About Actavis
Actavis plc
ACT, headquartered in Dublin, Ireland, is a unique
specialty pharmaceutical company focused on developing, manufacturing and
commercializing high quality affordable generic and innovative branded
pharmaceutical products for patients around the world.
Actavis markets a broad portfolio of branded and generic pharmaceuticals and
develops innovative medicines for patients suffering from diseases
principally in the central nervous system, gastroenterology, women's health,
urology, cardiovascular, respiratory and anti-infective therapeutic
categories. The company is an industry leader in product research and
development, with one of the broadest brand development pipelines in the
pharmaceutical industry, and a leading position in the submission of generic
product applications. Actavis has commercial operations in more than 60
countries and operates more than 30 manufacturing and distribution
facilities around the world.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in